映恩生物-B、药捷安康-B均创上市以来新高！此前被调入港股通标的名单_老虎社区_美港股上老虎

映恩生物-B、药捷安康-B均创上市以来新高！此前被调入港股通标的名单

老虎资讯综合09-08

9月8日，映恩生物-B涨幅扩大至18%、药捷安康-B涨幅扩大至20%，均创上市以来新高！此前被调入港股通标的名单，自今日起生效。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1167675110?lang=zh_CN&edition=full","thumbnail":"https://static.tigerbbs.com/fd680cd945fd32917c8ece66ec685e5f","is_english":false,"pubTime":"2025-09-08 10:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1167675110","market":"hk","top_or_hot":-1,"title":"映恩生物-B、药捷安康-B均创上市以来新高！此前被调入港股通标的名单","media":"老虎资讯综合","content":"<html><head></head><body><p>9月8日，<a href=\"https://laohu8.com/S/09606\">映恩生物-B</a>涨幅扩大至18%、<a href=\"https://laohu8.com/S/02617\">药捷安康-B</a>涨幅扩大至20%，均创上市以来新高！此前被调入港股通标的名单，自今日起生效。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/021fc951a6d34211ef4f7fd6aec0d228\" title=\"\" tg-width=\"560\" tg-height=\"240\"/></p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/96456377a774be3477351b032303a427\" title=\"\" tg-width=\"560\" tg-height=\"240\"/></p><p></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>映恩生物-B、药捷安康-B均创上市以来新高！此前被调入港股通标的名单</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n映恩生物-B、药捷安康-B均创上市以来新高！此前被调入港股通标的名单\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2025-09-08 10:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>9月8日，<a href=\"https://laohu8.com/S/09606\">映恩生物-B</a>涨幅扩大至18%、<a href=\"https://laohu8.com/S/02617\">药捷安康-B</a>涨幅扩大至20%，均创上市以来新高！此前被调入港股通标的名单，自今日起生效。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/021fc951a6d34211ef4f7fd6aec0d228\" title=\"\" tg-width=\"560\" tg-height=\"240\"/></p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/96456377a774be3477351b032303a427\" title=\"\" tg-width=\"560\" tg-height=\"240\"/></p><p></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"YANG","symbol_name":"三倍做空富时中国ETF-Direxion","start_time":0,"source_url":"","article_id":"1167675110","we_media_id":"102","thumbnails":["https://static.tigerbbs.com/fd680cd945fd32917c8ece66ec685e5f"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1167675110","pubTimestamp":1757299574,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"老虎资讯综合","introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"summary":"9月8日，$映恩生物-B(09606)$涨幅扩大至18%、$药捷安康-B(02617)$涨幅扩大至20%，均创上市以来新高！此前被调入港股通标的名单。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"YANG":"三倍做空富时中国ETF-Direxion","BK4614":"Manus概念股","09606":"映恩生物-B","BK1161":"生物科技","HK0000252160.HKD":"易方达 (香港) 中国股票股息基金A 类 (分派) 港元","HSTECH":"恒生科技指数","LU2543165471.USD":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","HSCEI":"国企指数","HK0000500386.USD":"易方达 (香港) 中国股票股息基金A 类 (累积) 美元","07226":"南方两倍做多恒科","02617":"药捷安康-B","HK0000252152.HKD":"易方达 (香港) 中国股票股息基金A 类 (累积) 港元"},"translate_title":"Yingen Bio-B and Yaojie Ankang-B both hit new highs since their listing! Previously transferred to the list of Hong Kong Stock Connect bids","themeId":"2ea7ccd6a31b3cd6d3ea988a9ba76c8b","isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/67690b3082074cf516b73afcf89b82d8","symbols_score_info":{"02617":1,"07226":1,"09606":1,"HSCEI":1,"HSTECH":1,"YANG":1},"content_text":"9月8日，映恩生物-B涨幅扩大至18%、药捷安康-B涨幅扩大至20%，均创上市以来新高！此前被调入港股通标的名单，自今日起生效。","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":1,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}